SCHEMBL2007999

SCHEMBL2007999

CCOC(=O)COc1ccc(C(=O)CNC(=O)OC(C)(C)C)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ CYP2C19 P33261 1/20 0.41
▸ ADRB3 P13945 2/20 0.41
▸ MAPT P10636 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ TSHR P16473 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NCOA1 Q15788 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NCOA3 Q9Y6Q9 1/20 0.39
▸ AAK1 Q2M2I8 1/20 0.39
▸ CASP1 P29466 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008176 0.90 KMT2A (0.44) GAAALDH1A1L3MBTL1MAPTMAPK1
SCHEMBL2013251 0.85 GAA (0.39) GAAALDH1A1L3MBTL1MAPTMAPK1
SCHEMBL2007940 0.85 NPC1 (0.42) GAAALDH1A1L3MBTL1MAPTMAPK1
SCHEMBL2012807 0.85 NPC1 (0.44) GAAALDH1A1L3MBTL1CYP2C19MAPK1
SCHEMBL2011477 0.82 GAA (0.40) GAAALDH1A1L3MBTL1TDP1ADRB3
SCHEMBL4851453 0.81 RORC (0.54) GAAALDH1A1L3MBTL1TDP1CYP2C19
SCHEMBL11112485 0.80 ALDH1A1 (0.53) GAAALDH1A1L3MBTL1TDP1ADRB3
SCHEMBL2008148 0.80 ALDH1A1 (0.43) GAAALDH1A1ADRB3MAPTMAPK1
SCHEMBL2010623 0.80 MAPK1 (0.36) GAAALDH1A1L3MBTL1MAPTMAPK1
SCHEMBL26921163 0.79 HPGD (0.47) ALDH1A1MAPTTSHRKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 — — US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 — — US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 — — US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 — — US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 — — EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 GAA 3340/4885ALDH1A1 2548/4885L3MBTL1 4640/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 GAA 3340/4885ALDH1A1 2548/4885L3MBTL1 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback